Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Shareholder walkthrough of Seneffe radiopharmaceutical manufacturing facility

Melbourne (Australia) – 28th April 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today provides further information on its recently acquired radiopharmaceutical manufacturing facility in Seneffe, Belgium.[1]

In response to considerable interest expressed by shareholders following Telix's Quarterly Shareholder Update conference call that was held on 22nd April 2020, the Company is pleased to provide a shareholder walkthrough of its Seneffe radiopharmaceutical manufacturing facility.

The purpose of this shareholder walkthrough is to provide a virtual tour of the facility, which will deliver a range of commercial benefits to Telix including the ability to manufacture a broad range of diagnostic and therapeutic radiopharmaceutical products in Europe in commercial quantities, under a Class IIA radiation licence.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telix.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

[1] ASX release 3rd April 2020